ReviewAdvanced healthcare materials2026
From Technological Innovation to Clinical Translation: Progress and Challenges in 3D Bioprinting for the Development of Breast Cancer Bone Metastasis Models.
Review in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The construction of 3D in vitro tumor models centered on bioprinting technology represents one of the most anticipated interdisciplinary innovations and medical applications in recent years. Breakthrough research achievements have been made in the construction of 3D-printed models for various tumors, with a small subset of these technologies advancing to the clinical research stage. However, due to the complex behavioral characteristics of breast cancer bone metastasis, traditional research models exhibit significant limitations and yield minimal mechanistic insights into therapeutic interventions. The irreproducible spatiotemporal dynamics and complex, both synergistic and antagonistic, interactions of multicellular and biochemical components within the bone-metastatic breast cancer microenvironment, which remains irreproducible using conventional techniques, are precisely what drive the unique translational value of 3D bioprinting technology in clinical applications. This article systematically reviews recent advances and clinical explorations in 3D bioprinting technology for breast cancer models, with a focused analysis and summary of four key aspects: printable biomaterials, fabrication processes, research advantages, and translational applications. Capitalizing on recent advances in artificial intelligence (AI) technologies, this review provides a cross-disciplinary analysis of the current state of clinically oriented research and identifies critical challenges that must be addressed to achieve breakthroughs. Furthermore, it systematically summarizes the key difficulties and obstacles encountered across various research directions. Through this comprehensive review, we aim to provide biomedical engineers and clinicians with systematic insights and technical references regarding 3D bioprinted models of breast cancer bone metastasis, thereby facilitating the advancement of highly practical research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.